Literature DB >> 9607352

Ethmoid sinus cancer: twenty-nine cases managed with primary radiation therapy.

J N Waldron1, B O'Sullivan, P Warde, P Gullane, F F Lui, D Payne, B Cummings.   

Abstract

PURPOSE: To describe the outcome of patients with carcinoma of the ethmoid sinus managed with a policy of primary radiation therapy with surgery for salvage of persistent or progressive disease. METHODS AND MATERIALS: A retrospective chart review was undertaken of 29 patients with the diagnosis of carcinoma of the ethmoid complex who underwent treatment in the period between January 1976 and December 1994 at the Princess Margaret Hospital. Analysis was confined to those patients with epithelial invasive histology (squamous carcinoma, adenocarcinoma, or undifferentiated carcinoma) managed with curative intent with primary radiation therapy. The median patient age was 62, with a median follow-up time of 4 years. Staging was assigned according to a modification of the UICC 1997 system with 19 (66%) of patients presenting with T4 category tumors. The most common radiation dose regimes were 60 Gy in 30 daily fractions over 6 weeks, or 50 Gy in 20 daily fractions over 4 weeks. Outcome was analyzed with respect to overall survival, cause-specific survival, and local progression-free survival. The influence of a variety of clinical and therapeutic factors on outcome is discussed, the patterns of disease failure are described, and the rationale for this treatment approach is outlined.
RESULTS: The 5-year rates of overall survival, cause-specific survival, and local progression-free survival were 39%, 58%, and 41%, respectively. A total of 18 of 29 patients died during the period of review. Of these, 12 deaths were due to ethmoid cancer, one was due to a second primary lung cancer, and five were attributed to nononcologic causes. No patients died due to treatment-related toxicity. Increasing T category predicted for worse outcome on univariate analysis. Local progression was the major cause of treatment failure and was documented in 15 of 29 patients treated (52%). Six patients were offered salvage surgery for local progression, of whom two remained disease free at 15 and 17 months follow-up.
CONCLUSIONS: Outcome of patients with ethmoid cancer managed with primary radiation therapy with surgery for salvage is comparable to that achieved with planned combined modality approaches. Nevertheless, outcome remains poor and is dependent on the local extent of tumor, with 40-50% of patients eventually succumbing to disease.

Entities:  

Mesh:

Year:  1998        PMID: 9607352     DOI: 10.1016/s0360-3016(98)00018-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Proton beam therapy for locally advanced and unresectable (T4bN0M0) squamous cell carcinoma of the ethmoid sinus: A report of seven cases and a literature review.

Authors:  Takashi Saito; Hitoshi Ishikawa; Kayoko Ohnishi; Teruhito Aihara; Masashi Mizumoto; Nobuyoshi Fukumitsu; Kaori Sugawara; Toshiyuki Okumura; Hideyuki Sakurai
Journal:  Oncol Lett       Date:  2015-05-15       Impact factor: 2.967

2.  Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity.

Authors:  Shamit Chopra; Dev P Kamdar; David S Cohen; Lance K Heilbrun; Daryn Smith; Harold Kim; Ho-Sheng Lin; John R Jacobs; George Yoo
Journal:  Laryngoscope       Date:  2016-11-15       Impact factor: 3.325

Review 3.  Proton beam radiation therapy for head and neck malignancies.

Authors:  Steven J Frank; Ugur Selek
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

4.  The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.

Authors:  L Madison Michael; Jeffrey M Sorenson; Sandeep Samant; Jon H Robertson
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

5.  Dosimetry of interface region near closed air cavities for Co-60, 6 MV and 15 MV photon beams using Monte Carlo simulations.

Authors:  Chandra P Joshi; Johnson Darko; P B Vidyasagar; L John Schreiner
Journal:  J Med Phys       Date:  2010-04

Review 6.  Paranasal sinus cancer: caveats and controversies.

Authors:  John Waldron; Ian Witterick
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

Review 7.  Management of paranasal sinus malignancy.

Authors:  Terry A Day; Ricardo A Beas; Rodney J Schlosser; Bradford A Woodworth; Julio Barredo; Anand K Sharma; M Boyd Gillespie
Journal:  Curr Treat Options Oncol       Date:  2005-01

8.  Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes.

Authors:  Stephanie E Combs; Stephan Konkel; Daniela Schulz-Ertner; Marc W Münter; Jürgen Debus; Peter E Huber; Christoph Thilmann
Journal:  Radiat Oncol       Date:  2006-07-21       Impact factor: 3.481

9.  Treatment Outcomes of Locally Advanced Squamous Cell Carcinoma of the Ethmoid Sinus Treated with Anterior Craniofacial Resection or Chemoradiotherapy.

Authors:  Takeharu Ono; Norimitsu Tanaka; Hirohito Umeno; Kiyohiko Sakata; Motohiro Morioka; Yoko Ohmaru; Hideaki Rikimaru; Noriyuki Koga; Kensuke Kiyokawa; Shun-Ichi Chitose; Buichiro Shin; Takeichiro Aso; Hidehiro Etoh; Toshi Abe
Journal:  Case Rep Oncol       Date:  2017-04-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.